Stocktoria
Transcode Therapeutics, Inc. RNAZ
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-04-28
Transcode Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $13.4M | $9.7M | $12.3M | $10.2M | $2.8M |
| Operating income | -$28.0M | -$15.7M | -$19.4M | -$18.6M | -$6.2M |
| Interest expense | — | $26,813 | $55,899 | $31,986 | $95,070 |
| Income tax | $226,069 | $0 | $0 | $0 | $53,051 |
| Net income | -$34.7M | -$16.8M | -$18.5M | -$17.6M | -$6.8M |
| EPS (diluted) | $-52.59 | $-1336.63 | $-3419.01 | $-1082.79 | $-0.81 |
| Operating cash flow | -$19.5M | -$13.3M | -$18.1M | -$15.8M | -$5.3M |
| Free cash flow | -$19.5M | -$13.4M | -$18.1M | -$15.9M | -$5.5M |
| Cash & equivalents | $17.8M | $5.8M | $2.8M | $5.0M | $20.8M |
| Total assets | $162.4M | $7.3M | $5.2M | $7.6M | $22.9M |
| Total liabilities | $10.5M | $9.3M | $3.5M | $4.3M | $2.5M |
| Shareholders' equity | $10.3M | -$2.0M | $1.6M | $3.2M | $20.4M |
Source: SEC EDGAR filings · CIK 0001829635 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.